Skip to main content

Advertisement

SpringerLink
Log in

Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The purpose of the present review was to provide a comprehensive picture of the efficacy of the different tumor necrosis factor (TNF)-α inhibiting agents in the treatment of acute anterior uveitis (AAU), the most common extra-articular manifestation of ankylosing spondylitis (AS). AS related, AAU may lead to severe visual impairment, due to frequent flare recurrences, anterior, and posterior segment complications and traditional treatment side effects. Considerably higher levels of tumor necrosis factor (TNF) have been assessed in the aqueous humor and inflamed joints of patients with AS. Anti-TNF drugs have shown efficacy in preventing relapses of rheumatological manifestations of spondyloarthropathies. Several studies have underlined the sustained efficacy of the monoclonal anti-TNF antibodies also in reducing the recurrence of anterior chamber flares in patients with AS-related AAU. On the other hand, retrospective studies and observational reports have indicated lower effectiveness and some paradoxical occurrence of uveitis following treatment with the soluble receptor agent etanercept. Growing evidence suggests that a prophylactic strategy could be advocated in subjects with frequent and recalcitrant attacks of AS-AAU. In this regard, the administration of monoclonal anti-TNF antibodies such as adalimumab (ADA) has been shown to significantly reduce the rate of AAU recurrences. Indeed, during ADA treatment about 90 % of patients have shown to remain completely free of attacks for the entire follow-up period, in most studies. Further studies are needed to confirm the long-term efficacy of TNF inhibitors in AS related AAU and also their role in preventing ocular complications and visual impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jones NP (2015) The Manchester uveitis clinic: the first 3000 patients—epidemiology and casemix. Ocul Immunol Inflamm 23:118–126

    Article  PubMed  Google Scholar 

  2. Karaconji T, Maconochie Z, McCluskey P (2013) Acute anterior uveitis in Sydney. Ocul Immunol Inflamm 21:108–114

    Article  CAS  PubMed  Google Scholar 

  3. Pato E, Bañares A, Jover JA, Fernández-Gutiérrez B, Godoy F, Morado C et al (2000) Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 27:2198–2202

    CAS  PubMed  Google Scholar 

  4. Canouï-Poitrine F, Kemta Lekpa F, Farrenq V, Boissinot V, Hacquardo-Bouder C, Comet D et al (2012) Prevalence and factors associated with uveitis in spondyloarthropathies patients in France: results from the EXTRA observational survey. Arthritis Care Res (Hoboken) 64:919–924

    Article  Google Scholar 

  5. Zeboulon N, Dougados M, Gossec L (2015) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67:955–959

    Article  Google Scholar 

  6. Rosenbaum JT (2015) Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol 34:999–1002

    Article  PubMed  Google Scholar 

  7. Sieper J, Rudwaleit M, Khan MA, Braun J (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20:401–417

    Article  PubMed  Google Scholar 

  8. Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Rajska BM et al (2005) A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. Arthritis Rheum 52:269–274

    Article  CAS  PubMed  Google Scholar 

  9. Nossent JC, Sagen-Johnsen S, Bakland G (2014) Tumor necrosis factor-α promoter −308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response. J Rheumatol 41:1675–1682

    Article  CAS  PubMed  Google Scholar 

  10. Xiang Q, Chen L, Fang J, Hou S, Wei L, Bai L et al (2013) TNF receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis. Arthritis Res Ther 15:R113

    Article  PubMed  PubMed Central  Google Scholar 

  11. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74:65–73

    Article  PubMed  Google Scholar 

  12. Chen CH, Lin KC, Chen HA, Liao HT, Liang TH, Wang HP et al (2007) Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. Clin Rheumatol 26:953–957

    Article  PubMed  Google Scholar 

  13. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D et al (2015) Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford) 54:633–640

    Article  Google Scholar 

  14. Haroon M, O’Rourke M, Ramasamy P, Murphy CC, FitzGerald O (2015) A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis 74:1990–1995

    Article  PubMed  Google Scholar 

  15. Robinson PC, Brown MA (2014) The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 16:109

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cantarini L, Fabbroni M, Talarico R, Costa L, Caso F, Cuneo GL et al (2015) Effectiveness of adalimumab in non-radiographic axial spondyloarthritis: evaluation of clinical and magnetic resonance imaging outcomes in a monocentric cohort. Medicine (Baltimore) 94, e1170

    Article  CAS  Google Scholar 

  17. D’Ambrosio EM, La Cava M, Tortorella P, Gharbyia M, Campanella M, Iannetti L (2016) Clinical features and complications of the HLA-B27-associated acute anterior uveitis: a meta-analysis. Semin Ophthalmol. doi:10.3109/08820538.2016.1170158

    Google Scholar 

  18. Rothova A, Buitenhuis HJ, Christiaans BJ, Linssen A, van der Gaag R, Kijlstra A et al (1983) Acute anterior uveitis (AAU) and HLA-B27. Br J Rheumatol 22(4 Suppl 2):144–145

    Article  CAS  PubMed  Google Scholar 

  19. D’Alessandro LP, Forster DJ, Rao NA (1991) Anterior uveitis and hypopyon. Am J Ophthalmol 112:317–321

    Article  PubMed  Google Scholar 

  20. Tuncer S, Adam YS, Urgancioglu M, Tugal-Tutkun I (2005) Clinical features and outcomes of HLA-b27-positive and HLA-B27-negative acute anterior uveitis in a Turkish patient population. Ocul Immunol Inflamm 13:367–373

    Article  CAS  PubMed  Google Scholar 

  21. Huhtinen M, Karma A (2000) HLA-B27 typing in the categorisation of uveitis in a HLA-B27 rich population. Br J Ophthalmol 84:413–416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sampaio-Barros PD, Conde RA, Bonfiglioli R, Bertolo MB, Samara AM (2006) Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int 26:1143–1146

    Article  PubMed  Google Scholar 

  23. Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS (1998) Outcomes in anterior uveitis associated with the HLA-B27 haplotype. Ophthalmology 105:1646–1651

    Article  CAS  PubMed  Google Scholar 

  24. Chang JH, McCluskey PJ, Wakefield D (2005) Acute anterior uveitis and HLA-B27. Surv Ophthalmol 50:364–388

    Article  PubMed  Google Scholar 

  25. Neri P, Azuara-Blanco A, Forrester JV (2004) Incidence of glaucoma in patients with uveitis. J Glaucoma 13:461–465

    Article  PubMed  Google Scholar 

  26. Loh AR, Acharya NR (2010) Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol 150:534–542

    Article  PubMed  PubMed Central  Google Scholar 

  27. Dodds EM, Lowder CY, Meisler DM (1999) Posterior segment inflammation in HLA-B27. acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm 7:85–92

    Article  CAS  PubMed  Google Scholar 

  28. Rodriguez A, Akova YA, Pedroza-Seres M, Foster CS (1994) Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology 101:1267–1274

    Article  CAS  PubMed  Google Scholar 

  29. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estévez E (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20:155–157

    Article  PubMed  Google Scholar 

  30. Khera TK, Dick AD, Nicholson LB (2010) Mechanisms of TNF alpha regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res 29:610e21

    Article  Google Scholar 

  31. Ferguson TA, Griffith TS (2007) The role of Fas ligand and TNF related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy 92:140e54

    Google Scholar 

  32. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R et al (2001) Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophthalmic Res 33:251e5

    Article  Google Scholar 

  33. Sakaguchi M, Sugita S, Sagawa K, Itoh K, Mochizuki M (1998) Cytokine production by T cells infiltrating in the eye of uveitis patients. Jpn J Ophthalmol 42:262e8

    Article  Google Scholar 

  34. Hangai M, He S, Hoffmann S, Lim JI, Ryan SJ, Hinton DR (2006) Sequential induction of angiogenic growth factors by TNFalpha in choroidal endothelial cells. J Neuroimmunol 171:45e56

    Article  Google Scholar 

  35. Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S et al (1998) Tumor necrosis factor alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 273:22128e35

    Article  Google Scholar 

  36. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36:801–808

    Article  CAS  PubMed  Google Scholar 

  37. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71:700–706

    Article  CAS  PubMed  Google Scholar 

  38. Machado MA, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EI et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33:2199–2213

    Article  CAS  PubMed  Google Scholar 

  39. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543–1551

    Article  CAS  PubMed  Google Scholar 

  40. Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A et al (2010) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 30:1437–1440

    Article  PubMed  Google Scholar 

  41. Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA et al (2012) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis 71:878–884

    Article  CAS  PubMed  Google Scholar 

  42. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690–1699

    Article  CAS  Google Scholar 

  43. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P et al (2016) Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 68:1522–1530

    Article  CAS  PubMed  Google Scholar 

  44. Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT et al (2016) Adalimumab for Ocular Inflammation. Ocul Immunol Inflamm 22:1–8

    Article  Google Scholar 

  45. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M et al (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66:419–421

    Article  CAS  PubMed  Google Scholar 

  46. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Bonilla G, Ruiz-Sancho D et al (2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30:1277–1279

    PubMed  Google Scholar 

  47. Benitez-del-Castillo JM, Garia-Sanchez J, Iradier T, Banares A (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14:340–343

    Article  PubMed  Google Scholar 

  48. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785–796

    Article  PubMed  Google Scholar 

  49. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896–904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447–2451

    Article  CAS  PubMed  Google Scholar 

  51. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68:696–701

    Article  CAS  PubMed  Google Scholar 

  52. van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE (2014) Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol 41:1843–1848

    Article  PubMed  Google Scholar 

  53. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M et al (2006) Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis 65:1631–1634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wendling D, Joshi A, Reilly P, Mittal M, Bao Y (2014) Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res & Opin 30:2515–2521

    Article  CAS  Google Scholar 

  55. Migliore A, Bizzi E, Bernardi M, Picchianti Diamanti A, Laganà B (2015) Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Colin Drug Invesst 35:23–29

    Article  CAS  Google Scholar 

  56. Kim M, Won JY, Choi SY, Ju JH, Park YH (2016) Anti-TNFα treatment for HLA-B27 positive ankylosing spondylitis-related uveitis. Am J Ophthalmol. doi:10.1016/j.ajo.2016.07.016

    Google Scholar 

  57. Raffeiner B, Ometto F, Bernardi L, Botsios C, Punzi L (2014) Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Rep Med 2014:2014471319

    Google Scholar 

  58. Killian M, Touraine R, Amouzougan A, Thomas T, Marotte H (2015) Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis. Ann Rheum Dis 74, e22

    Article  PubMed  Google Scholar 

  59. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M (2014) New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther 14:583–600

    Article  CAS  PubMed  Google Scholar 

  60. Lian F, Zhou J, Wei C, Wang Y, Xu H, Liang L (2015) Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population. Clin Rheumatol 34:1913–1920

    Article  PubMed  Google Scholar 

  61. Sieper J, Landed R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ et al (2015) Effect if certolizumab peg over ninety-six weeks in patients with axial spindyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol 67:688–77

    Google Scholar 

  62. Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F et al (2015) Impact of certolizumab peg on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken) 67:1475–1480

    Article  CAS  Google Scholar 

  63. Llorenc V, Mesquida M, Sainz de La Maza M, Blanco R, Calvo V, Maiz O et al (2016) Certolizumab pegol, a new anti-TNF-alpha in the armamentarium against ocular inflammation. Ocul Immunol Inflamm 24:167–172

    CAS  PubMed  Google Scholar 

  64. Rudwaleit M, Rosenbaum JT, Landed R, Marzo-ortega H, Sieper J, van der Heijde D (2016) Observed Incidence of uveitis following certolizumab peg treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken) 68:838–844

    Article  CAS  Google Scholar 

  65. Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V (2014) Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 22:90–95

    Article  CAS  PubMed  Google Scholar 

  66. Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V (2013) Golimumab treatment for complicated uveitis. Clinical Exp Rheumatol 31:320–321

    Google Scholar 

  67. Cordero-Coma M, Calvo-Rio V, Adan A, Blanco R, Alvarex-Castro C, Mesquida M et al (2014) Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators of Inflamm 2014:717598

    Article  Google Scholar 

  68. Faez S, Lobo AM, Sobrin L, Papaliodis GN (2014) Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Opthalmolol 42:392–395

    Article  Google Scholar 

  69. Calvo-Rio V, de la Hera D, Blanco R, Beltran-Catalan E, Loricera J, Canal J et al (2014) Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 32:864–868

    PubMed  Google Scholar 

  70. Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A et al (2016) Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum 46:95–101

    Article  PubMed  Google Scholar 

  71. Sampaio-Barros PD, van der Horst-Bruinsma IE (2014) Adverse effects of TNF inhibitors in SPA: are they different from RA? Best Pract Res Clin Rheumatol 28:747–763

    Article  PubMed  Google Scholar 

  72. Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH et al (2015) The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a meta-analysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 42:2229–2237

    Article  CAS  PubMed  Google Scholar 

  73. Martin-Mola E, Sieper J, LEirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R et al (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 28:238–245

    CAS  PubMed  Google Scholar 

  74. Moisseiev E, Shulman S (2014) Certolizumab-induced uveitis: a case report and review of the literature. Case Rep Ophthalmic 5:54–59

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Humanitas Research Hospital, Rozzano, Milan, Italy

    Claudia Fabiani

  2. Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, University of Siena, Siena, Italy

    Antonio Vitale, Bruno Frediani & Luca Cantarini

  3. Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

    Giuseppe Lopalco & Florenzo Iannone

Authors
  1. Claudia Fabiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Lopalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Florenzo Iannone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bruno Frediani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Fabiani.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fabiani, C., Vitale, A., Lopalco, G. et al. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 35, 2631–2638 (2016). https://doi.org/10.1007/s10067-016-3426-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3426-3

Keywords

Search

Navigation